TGTX vs. PTCT, DCPH, INSM, CCXI, SAGE, CTLT, ROIV, ELAN, ASND, and LEGN
Should you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include PTC Therapeutics (PTCT), Deciphera Pharmaceuticals (DCPH), Insmed (INSM), ChemoCentryx (CCXI), Sage Therapeutics (SAGE), Catalent (CTLT), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical preparations" industry.
PTC Therapeutics (NASDAQ:PTCT) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, community ranking, valuation, risk and institutional ownership.
PTC Therapeutics currently has a consensus price target of $35.67, suggesting a potential downside of 1.20%. TG Therapeutics has a consensus price target of $29.83, suggesting a potential upside of 79.29%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TG Therapeutics is more favorable than PTC Therapeutics.
TG Therapeutics received 110 more outperform votes than PTC Therapeutics when rated by MarketBeat users. Likewise, 76.77% of users gave TG Therapeutics an outperform vote while only 61.83% of users gave PTC Therapeutics an outperform vote.
In the previous week, PTC Therapeutics had 11 more articles in the media than TG Therapeutics. MarketBeat recorded 14 mentions for PTC Therapeutics and 3 mentions for TG Therapeutics. PTC Therapeutics' average media sentiment score of 1.25 beat TG Therapeutics' score of 0.44 indicating that TG Therapeutics is being referred to more favorably in the news media.
PTC Therapeutics has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.33, suggesting that its share price is 133% more volatile than the S&P 500.
TG Therapeutics has lower revenue, but higher earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
TG Therapeutics has a net margin of 14.24% compared to TG Therapeutics' net margin of -62.45%. PTC Therapeutics' return on equity of 31.34% beat TG Therapeutics' return on equity.
58.6% of TG Therapeutics shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by company insiders. Comparatively, 9.2% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
TG Therapeutics beats PTC Therapeutics on 16 of the 18 factors compared between the two stocks.
Get TG Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TG Therapeutics Competitors List
Related Companies and Tools
